Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph phase_4
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 11 (50.0%)
Phase 41 (50.0%)

Trials by Status

recruiting2100%

Recent Activity

2 active trials
Showing 2 of 2
recruitingphase_1

Inflammatory Challenge and Fear

NCT06630884
recruitingphase_4

Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT

NCT05745987

Clinical Trials (2)

Showing 2 of 2 trials
NCT06630884Phase 1

Inflammatory Challenge and Fear

Recruiting
NCT05745987Phase 4

Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2